Device review "consumer-oriented" performance goals under development by FDA.
This article was originally published in The Gray Sheet
FDA DEVICE REVIEW "CONSUMER-ORIENTED" PERFORMANCE GOALS UNDER DEVELOPMENT at the agency as part of a pilot pro-gram to be proposed under the Government Performance and Results Act of 1993, according to agency staffers. The bill (S 20), which was signed into law on Aug. 3, 1993, calls on the federal government to improve "program effectiveness and public accountability by promoting a new focus on results, service quality, and customer satisfaction."
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.